v3.22.2.2

Segment Reporting | 12 Months Ended
--- | ---
Jun. 30, 2022
Segment Reporting [Abstract] |
Segment Reporting | 25. Segment Reporting In accordance with FASB ASC 280, “Segment Reporting,” the Company discloses financial and descriptive information about its reportable segments. The Company operates in two segments, (i) Biopharmaceuticals, our biologics development and licensing activities, conducted within iBio, Inc. and (ii) Bioprocessing, our CDMO segment, conducted within iBio CDMO. These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The accounting policies of the segments are the same as those described in the Summary of Significant Accounting Policies. Please note that certain totals may not sum due to rounding. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Biopharmaceuticals |  | Bioprocessing |  | ​ |  | ​
Year Ended June 30, 2022 (in thousands) |  | iBio, Inc. |  | iBio CDMO |  | Eliminations |  | Total
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenues - external customers | ​ | $ | 1,884 | ​ | $ | 499 | ​ | $ | — | ​ | $ | 2,383
Revenues - intersegment | ​ | ​ | 1,586 | ​ | ​ | 2,455 | ​ | ​ | (4,041) | ​ | ​ | —
Cost of goods sold | ​ | ​ | — | ​ | ​ | 216 | ​ | ​ | — | ​ | ​ | 216
Gross profit | ​ | ​ | 3,470 | ​ | ​ | 2,739 | ​ | ​ | (4,041) | ​ | ​ | 2,167
Research and development | ​ |  | 11,819 | ​ | ​ | 8,260 | ​ | ​ | (2,350) | ​ |  | 17,729
General and administrative | ​ |  | 20,844 | ​ | ​ | 14,975 | ​ | ​ | (1,691) | ​ |  | 34,128
Operating loss | ​ |  | (29,194) | ​ | ​ | (20,496) | ​ | ​ | — | ​ |  | (49,690)
Interest expense | ​ |  | — | ​ | ​ | (1,412) | ​ | ​ | — | ​ |  | (1,412)
Forgiveness of note payable and accrued interest | ​ | ​ | — | ​ | ​ | 607 | ​ | ​ | — | ​ | ​ | 607
Interest and other income | ​ |  | 184 | ​ | ​ | 7 | ​ | ​ | — | ​ |  | 191
Consolidated net loss | ​ |  | (29,010) | ​ | ​ | (21,295) | ​ | ​ | — | ​ |  | (50,305)
Total assets | ​ |  | 156,893 | ​ | ​ | 43,092 | ​ | ​ | (100,578) | ​ |  | 99,407
Finance lease ROU assets | ​ |  | — | ​ | ​ | 74 | ​ | ​ | — | ​ |  | 74
Operating lease ROU assets | ​ | ​ | 3,068 | ​ | ​ | 1,952 | ​ | ​ | — | ​ | ​ | 5,020
Fixed assets, net of accumulated depreciation | ​ | ​ | 1,373 | ​ | ​ | 35,288 | ​ | ​ | — | ​ | ​ | 36,661
Intangible assets, net of accumulated amortization | ​ |  | 4,851 | ​ |  | — | ​ |  | — | ​ |  | 4,851
Amortization of ROU assets | ​ |  | — | ​ |  | 599 | ​ |  | — | ​ |  | 599
Depreciation expense | ​ |  | — | ​ |  | 2,275 | ​ |  | — | ​ |  | 2,275
Amortization of intangible assets | ​ | ​ | 401 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 401
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Biopharmaceuticals | ​ | Bioprocessing | ​ | ​ | ​ | ​
Year Ended June 30, 2021 (in thousands) |  | iBio, Inc. | ​ | iBio CDMO | ​ | Eliminations | ​ | Total
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenues - external customers | ​ | $ | 1,098 | ​ | $ | 1,274 | ​ | $ | — | ​ | $ | 2,371
Revenues - intersegment | ​ | ​ | 1,017 | ​ | ​ | 1,307 | ​ | ​ | (2,324) | ​ | ​ | —
Cost of goods sold | ​ | ​ | 425 | ​ | ​ | 1,037 | ​ | ​ | — | ​ | ​ | 1,462
Gross profit | ​ | ​ | 1,690 | ​ | ​ | 1,543 | ​ | ​ | (2,324) | ​ | ​ | 909
Research and development | ​ |  | 2,960 | ​ |  | 8,370 | ​ |  | (1,341) | ​ |  | 9,989
General and administrative | ​ |  | 13,429 | ​ |  | 9,585 | ​ |  | (983) | ​ |  | 22,031
Operating loss | ​ |  | (14,699) | ​ |  | (16,412) | ​ |  | — | ​ |  | (31,111)
Interest expense | ​ |  | — | ​ |  | (2,454) | ​ |  | — | ​ |  | (2,454)
Settlement income | ​ | ​ | 10,200 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 10,200
Interest and royalty income | ​ |  | 151 | ​ |  | 1 | ​ |  | — | ​ |  | 152
Consolidated net loss | ​ |  | (4,349) | ​ |  | (18,864) | ​ |  | — | ​ |  | (23,213)
Total assets | ​ |  | 175,272 | ​ |  | 35,721 | ​ |  | (64,025) | ​ |  | 146,968
Finance lease ROU assets | ​ |  | — | ​ |  | 26,111 | ​ |  | — | ​ |  | 26,111
Fixed assets, net of accumulated depreciation | ​ | ​ | — | ​ | ​ | 8,628 | ​ | ​ | — | ​ | ​ | 8,628
Intangible assets, net of accumulated amortization | ​ | ​ | 952 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 952
Amortization of finance lease ROU assets | ​ |  | — | ​ |  | 1,651 | ​ |  | — | ​ |  | 1,651
Depreciation expense | ​ |  | — | ​ |  | 472 | ​ |  | — | ​ |  | 472
Amortization of intangible assets | ​ |  | 291 | ​ |  | — | ​ |  | — | ​ |  | 291
​ ​​

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration